Hormone receptor positive HER2 negative breast cancer
Not yet recruitingEfficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer
Efficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer
- Disease:Hormone receptor positive HER2 negative breast cancer
- Substances:CyclophosphamideDocetaxel+3
Austria- Participants:18–64 years · 65+ years
- Substances:Cyclophosphamide
- Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group



